Osteopore Limited announce it has signed an agreement to sponsor two clinical trials in Brisbane, Australia, to further evaluate and validate the clinical use of its next-generation cranial and long bone reconstruction scaffolds. Brisbane-based Dr. Michael Wagels, a world-recognised plastic and reconstructive surgeon will lead a team of specialist surgeons who will undertake a comprehensive study of Osteopore's next-generation 3D-printed medical grade polycaprolactone/tricalcium phosphate (PCL-TCP) scaffolds and the surgical technique used to implant them in patients. Further clinical investigation has been instigated after encouraging results in several first-in-human cases. These include reconstruction of two tibias, one midface, two mandibles and one skull. Both studies are single-arm feasibility trials and each one will involve the recruitment of 10 patients who Dr. Wagels and the team at the Australian Centre for Complex Integrated Surgical Solutions will follow closely for up to five years. Trial patients will be treated at the Princess Alexandra Hospital in Brisbane and supported by the Herston Biofabrication Institute, with future expansion to the Royal Brisbane and Women's Hospital. One study will evaluate Osteopore's PCL-TCP scaffold system with corticoperiosteal tissue transfer for the reconstruction of acquired calvarial or upper cranial defects in adults. The other study will evaluate the Company's PCL-TCP scaffold system with corticoperiosteal tissue transfer for the reconstruction of critical sized lower limb bone defects. The trials will validate the clinical technique of using the corticoperiosteal flap in combination with these next- generation products and will provide Osteopore with important patient data to further support market adoption and penetration.